DebraLRichardsonMD

Obstetrics & Gynecology • Oklahoma City, OK

Gynecologic Oncology

Associate Professor, Gynecologic Oncology at Stephenson Cancer Center

Join to view full profile

Dr. Richardson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Richardson's full profile

Already have an account?

Office
800 NE 10th St
Oklahoma City, OK 73104
Phone+1 405-271-7770

Education & Training

Ohio State University/Mt Carmel HospitalFellowship, Gynecologic Oncology, 2006 - 2009
University of ConnecticutResidency, Obstetrics and Gynecology, 2001 - 2005
New York Medical CollegeClass of 2001

Certifications & Licensure

OK State Medical License 2017 - 2025
TX State Medical License 2009 - 2020
MN State Medical License 2005 - 2011
OH State Medical License 2006 - 2009
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Start of enrollment: 2020 Jun 29
Completed
Phase 1
Roles: Contact
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Start of enrollment: 2022 Jul 25
Active, not recruiting
Phase 2
Roles: Principal Investigator
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) Start of enrollment: 2022 Aug 31
Recruiting
Phase 3
Roles: Contact, Principal Investigator
PRO1184 for Advanced Solid Tumors Start of enrollment: 2022 Dec 07
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le
Journal for Immunotherapy of Cancer. 2025-01-11
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
Devalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, Mary F Mulcahy, Aparna Kalyan
Cancer. 2025-01-01
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892).
Sarah E Taylor, Sarah Behr, Kristine L Cooper, Haider Mahdi, Denise Fabian
Cancer Chemotherapy and Pharmacology. 2024-12-14

Press Mentions

Mersana Therapeutics to Provide Update on the Progress of Its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I StudySeptember 1st, 2021
Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
Group Is Established to Connect, Inspire and Empower UCI Women in TechnologyAugust 12th, 2020
Join now to see all